GOSS News and Press, Gossamer Bio Inc. From 07/24/23

- Call will be held on Tuesday, July 25 th beginning at 10 a.m. EDT - Gossamer Bio, Inc. (Nasdaq: GOSS), a clinical-stage biopharmaceutical company focused on the development and commercialization of seralutinib for the treatment of pulmonary arterial hypertension (PAH), announced t...

2023-07-20 08:33:09 ET Biopharmaceutical company Gossamer Bio ( NASDAQ: GOSS ) said on Thursday that it is set to offer securities in an ~$212M private placement. The company has entered into a securities purchase agreement with institutional and accredited investors. Goss...

2023-07-20 08:29:22 ET Netcapital NCPL -42% on $1.2M equity offering . Gossamer Bio ( GOSS ) -21% announces $212 Million private placement financing . DURECT Corporation ( DRRX ) -19% announces $15 Million Registered Direct Offering . Jianzhi Ed...

- In Conjunction with Offering, Interim TORREY OLE Data and PROSERA Phase 3 Design Disclosed via 8-K; Conference Call to Discuss Data and Phase 3 Design with Leading PAH KOLs to be Held on July 25 th - Gossamer Bio, Inc. (Nasdaq: GOSS), a clinical-stage biopharmaceutical company foc...

2023-06-14 10:03:06 ET Gainers: Inventiva ( IVA ) +25% . Gossamer Bio ( GOSS ) +21% . Akoya Biosciences ( AKYA ) +19% . InVivo Therapeutics ( NVIV ) +14% . Bone Biologics ( BBLG ) +13% . Losers: IO Biotech ( IOBT ...

2023-06-14 08:32:59 ET IO Biotech ( IOBT ) +33% Announces Achievement of Significant Phase 3 Clinical Trial Recruitment Milestone. WiSA Technologies ( WISA ) +36% . Inventiva ( IVA ) +35% announces positive topline results from the investigator-initia...

2023-05-20 10:30:00 ET Get ahead of the market by subscribing to Seeking Alpha's Stocks to Watch, a preview of key events scheduled for the coming week. The newsletter keeps you informed of the biggest stories set to make headlines, including upcoming IPOs, investor days, earnings reports a...

2023-05-19 15:00:19 ET Welcome to Seeking Alpha's Catalyst Watch - a breakdown of some of next week's actionable events that stand out. Check out Saturday morning's regular Stocks to Watch article for a full list of events planned for the week, or the Seeking Alpha earnings calendar ...

Gossamer Bio, Inc. (Nasdaq: GOSS), a clinical-stage biopharmaceutical company focused on the development and commercialization of seralutinib for the treatment of pulmonary arterial hypertension (PAH), today announced data from its Phase 2 TORREY Study of seralutinib in patients with PAH will be ...

2023-05-10 15:14:24 ET Gossamer Bio ( NASDAQ: GOSS ) is undergoing a strategic restructuring that includes laying off more than 25% of its employees and focusing exclusively on seralutinib for pulmonary arterial hypertension. The company said it is on schedule to begin a ...